Abstract 240P
Background
Cervical cancer is one of the leading causes of morbidity and mortality among women from cancer of the reproductive organs in developing countries. The purpose of this study is to analyze the dynamics of morbidity and mortality from cervical cancer in the Republic of Kazakhstan.
Methods
Mortality and morbidity rates were calculated for the period 2007-2016. 95% confidence intervals are presented. Incidence of and mortality rates were calculated per 100,000 (0/0000) of female population. All statistical calculations were performed using SPSS (Statistical Package for the Social Sciences) software, version 20.0 for Windows.
Results
For the period from 2007 to 2016, the incidence rates of cervical cancer were analyzed, which varied from 15.24 to 18.83 per 100,000 of female population. Mortality rates tended to decline over the 10-year period under review in 2007, reaching 7.8 to 7.0 per 100,000 of female population in 2016. There is a difference in morbidity and mortality from cervical cancer between different regions of Kazakhstan. An analysis of the distribution of the incidence in the Republic of Kazakhstan revealed the highest incidence rates in the northern region of the country 28.2 (95% CI: 23.6-33.5) and the north-eastern region 27.3 (95% CI: 22.4-32.9) per 100,000 of female population. On the other hand, the lowest morbidity and mortality rates were found in the southern region substituted 10.4 (95% CI: 7.4-14.2) and 5.4 (95% CI: 4.3-6.8) per 100,000 of female population respectively.
Conclusions
Thus, the incidence of cervical cancer in the Republic of Kazakhstan has increased over the 10-year period in question, while mortality rates have been gradually decreasing. Such trends can result from the national screening program which was implemented in Kazakhstan.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
Presenter: Peng Song
Session: Poster display session
Resources:
Abstract
519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
Presenter: Chih-Hsi Kuo
Session: Poster display session
Resources:
Abstract
521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
Presenter: Keisuke Baba
Session: Poster display session
Resources:
Abstract
526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Li Chu
Session: Poster display session
Resources:
Abstract
499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
Presenter: Oscar Siu Hong Chan
Session: Poster display session
Resources:
Abstract
489P - Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Presenter: Maximilian J. Hochmair
Session: Poster display session
Resources:
Abstract
509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial
Presenter: Andrea Camerini
Session: Poster display session
Resources:
Abstract
500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations
Presenter: Jianchun Duan
Session: Poster display session
Resources:
Abstract
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Presenter: Xingliang Li
Session: Poster display session
Resources:
Abstract
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract